Volume: 43 Issue: 2
Year: 2023, Page: 805-807, Doi: https://doi.org/10.51248/.v43i02.2554
About 40%–60% of obsessive-compulsive disorder patients do not achieve full remission even when treated with selective serotonin reuptake inhibitor and cognitive behavioural therapy. Here, we describe a case of a 30-year-old female suffering from OCD, who was not improved even after fluoxetine 80 mg per day and behavioural therapy and was successfully treated with low dose fluoxetine (60 mg/day) and Endoxifen (8 mg/day).
Keywords: Endoxifen; Obsessive compulsive disorder; OCD.
1. Klimke, A., Nitsche, M.A., Maurer, K., Voss, U. Case report: Successful treatment of therapy-resistant OCD with application of transcranial alternating current stimulation (tACS). Brain Stimul. 2016; 9(3):463-465.
2. Zhang, C., Zhang, Y., Li, D., Deng, Z., Nuttin, B., Voon, V., et al., Habenular stimulation for neurosurgery resistant obsessive-compulsive disorder: A case report. Front Psychiatry. 2020; 11:29.
3. Robbins, T.W., Vaghi, M.M., Banca, P. Obsessive-Compulsive Disorder: Puzzles and Prospects. Neuron. 2019; 102(1):27-47.
4. Eitan, R., Arkadir, D., Linetsky, E., Bick, A.S., Gilad, M., Freedman, S., et al., deep brain stimulation for obsessive compulsive disorder: case report of the first OCD patient in Israel. Harefuah. 2019;158 (7):418-422.
5. Grassi, G., Cecchelli, C., Vignozzi, L., Pacini, S. Investigational and experimental drugs to treat obsessive-compulsive disorder. J Exp Pharmacol. 2021; 12:695-706.
6. Ahmad, A., Sheikh, S., Shah, T., Reddy, M.S., Prasad, B., Verma, K.K., et al., Endoxifen, a new treatment option for mania: A double-blind, active-controlled trial demonstrates the antimanic efficacy of Endoxifen. Clin Transl Sci. 2016; 9(5): 252-259.
7. Ahmad, A., Sheikh, S., Khan, M.A., Chaturvedi, A., Patel, P., Patel, R., et al., Endoxifen: A new, protein kinase C inhibitor to treat acute and mixed mania associated with bipolar I disorder. Bipolar Disord. 2021;23(6):595-603
8. Abrial, E., Bétourné, A., Etiévant, A., Lucas, G., Scarna, H., Lambás-Señas, L., et al., Protein kinase C inhibition rescues manic-like behaviours and hippocampal cell proliferation deficits in the sleep deprivation model of mania. Int J Neuropsychopharmacol. 2014 ; 18(2):pyu031.
9. Ali, S.M., Ahmad, A., Shahabuddin, S., Ahmad, M.U., Sheikh, S., Ahmad, I. Endoxifen is a new potent inhibitor of PKC: a potential therapeutic agent for bipolar disorder. Bioorg. Med Chem Lett. 2010;20(8):2665-2667.
10. Battaini, F. Protein kinase C isoforms as therapeutic targets in nervous system disease states. Pharmacol Res. 2001; 44(5): 353-361.
11. Harwood, A.J. Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited. Mol Psychiatry. 2005; 10(1):117-126.
12. Marazziti, D., Masala, I., Rossi, A., Hollander, E., Presta, S., Giannaccini, G., et al., Increased inhibitory activity of protein kinase C on the serotonin transporter in OCD. Neuropsychobiology. 2000;41(4):171-177
Sivabalan Elangovan, Jayashri Sundaramoorthy, Saritha Dhuruvasan. Real world experience of Endoxifen augmentation therapy in a case of resistant OCD. Biomedicine: 2023; 43(2): 805-807